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DOI 10.1016/j.ccr.2011.06.020SUMMARYPathways defining susceptibility of normal cells to oncogenic transformation may be valuable therapeutic
targets. We characterized the cell of origin and its critical pathways in MN1-induced leukemias. Common
myeloid (CMP) but not granulocyte-macrophage progenitors (GMP) could be transformed by MN1. Comple-
mentation studies of CMP-signature genes in GMPs demonstrated that MN1-leukemogenicity required the
MEIS1/AbdB-like HOX-protein complex. ChIP-sequencing identified common target genes of MN1 and
MEIS1 and demonstrated identical binding sites for a large proportion of their chromatin targets. Transcrip-
tional repression ofMEIS1 targets in establishedMN1 leukemias demonstrated antileukemic activity. AsMN1
relies on but cannot activate expression of MEIS1/AbdB-like HOX proteins, transcriptional activity of these
genes determines cellular susceptibility toMN1-induced transformation andmay represent a promising ther-
apeutic target.INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive neoplastic
disease that is characterized by enhanced proliferation, blocked
differentiation, and dysregulated apoptosis. AML has been
recognized as heterogeneous on morphologic, cytogenetic,
and molecular levels. Fusion genes, acquired mutations, andSignificance
The cancer stem cell concept postulates a hierarchical organiz
this hierarchy. Whether cancer stem cells derive from normal
properties during transformation remains elusive. Moreover, p
have not been characterized. Employing single cell transfor
progenitor cells, we identify a narrow window of transformatio
formation susceptibility required the activity of a well-chara
demonstrated antileukemic activity, suggesting that transform
range of malignancies.dysregulated gene expression have been identified as leukemo-
genic events in AML patients. Not only is heterogeneity recog-
nized between patients, but also between AML cells from one
patient. Studies showing that only a small proportion of AML
cells were clonogenic in culture (Buick et al., 1977) and that
only a small fraction of AML blood blasts could transfer disease
to immune-deficient mice (Bonnet and Dick, 1997; Lapidot et al.,ation of tumors with cancer stem cells residing at the top of
stem cells or whether committed cells reacquire stem cell
athways determining cellular susceptibility to transformation
mation of prospectively isolated hematopoietic stem and
n susceptibility during hematopoietic differentiation. Trans-
cterized self-renewal pathway. Inhibition of this pathway
ation susceptibility may be a therapeutic target in a wide
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Figure 1. CMPs, but Not GMPs, Are Susceptible to MN1-Induced Transformation
(A) Cumulative CFC yield is shown for an initial plating of 1000 MN1-expressing cells derived from a single cell sorted CMP (mean ± SD of 5 independent
experiments; single cell sorted CMPs were transduced with MN1 and 5 independent proliferating clones were evaluated in duplicate CFC assays).
(B) Survival analysis of mice transplanted with MN1-transduced cells derived from single cell sorted CMPs (n = 16 mice from 4 single cell-infected CMP clones)
and GMPs (n = 11 mice from 3 single cell-infected GMP clones and 3 bulk infected, sorted GMPs [130, 4000, and 10,000 sorted GMPs]).
(C) Secondary transplantation analysis. Bone marrow of primary leukemic MN1-CMP mice was transplanted into secondary mice (n = 14 from 5 primary mice),
and survival times were compared to primary transplants.
(D) Representative Wright-Giemsa stained cytospin preparation of bone marrow cells from leukemic mice (scale bars represent 50 mm in the upper panel and
10 mm in the lower panel).
(E) Spleen from a moribund leukemic mouse transplanted with MN1-CMP cells (scale bar, 1 cm).
(F) Average spleen weight of leukemic MN1-CMPmice and mice transplanted with bulk infected bone marrow compared to mice transplanted with normal bone
marrow cells (mean ± SD).
(G) Immunophenotype of leukemic MN1-CMP compared to bulk infected bone marrow cells frommoribund mice (mean ± SD). Expression of markers other than
B220 were not significantly different.
*In MN1-bulk cells, percentage of cells positive for CD4 and CD8 is shown.
(H) Myeloid progenitor-cell immunophenotype of leukemic bone marrow cells from a MN1-CMP mouse.
*Frequencies in gates are percentages from all viable cells. Cells with CMP phenotype fall within the lower right quadrant.
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Cell of Origin in MN1 Leukemia1994) provided evidence for a hierarchical cellular organization
of human AML.
AML cells that can initiate leukemia in xenotransplant models
are operationally defined as leukemia-initiating cells (LIC). Since
AML LICs and normal human hematopoietic stem cells (HSC)
were characterized by a CD34+ CD38 surface phenotype
(Bonnet and Dick, 1997; Miyamoto et al., 2000), it was specu
lated that AML LICs originate from HSCs (Passegue et al.,
2003). However, additional studies in chronic myeloid leukemia
patient samples or mouse models of human leukemia identified
LICs with immunophenotypic characteristics of myeloid or even
lymphoid progenitor cells (Deshpande et al., 2006; Jamieson
et al., 2004; Kirstetter et al., 2008; Somervaille and Cleary,
2006). These studies suggested that leukemic transformation
may also occur at the level of progenitor cells by conferring
self-renewal properties to committed progenitor cells. However,
the phenotype of LICs in established leukemias may be deter
mined by the oncogenic event rather than reflecting the pheno
type of the originating cell, and thus the phenotype of LICs
may not be indicative of the cell of origin. Other studies therefore
prospectively isolated hematopoietic stem and progenitor cells
and retrovirally introduced oncogenes in these cells to identify
possible cells of origin in these leukemias. The fusion oncopro
teins MLL-ENL, MLL-AF9, and MOZ-TIF2 that are found in
human AML patients have the capacity to transform prospec
tively isolated common myeloid progenitors (CMP) and/or granu
locyte-macrophage progenitors (GMP) (Chen et al., 2008a; Coz
zio et al., 2003; Huntly et al., 2004; Krivtsov et al., 2006), demon
strating that CMPs, in addition to HSCs, can be cells of origin in
leukemic transformation. These studies concluded that
leukemia-associated oncogenes confer self-renewal properties
to committed hematopoietic progenitors to allow unlimited
expansion of the leukemic clone. However, the cellular and
molecular characteristics of normal hematopoietic cells that
confer susceptibility to transformation remain elusive.
Two types of observations suggest that intrinsic properties of
normal cells may play a critical role in transformation. First, there
is no evidence that terminally differentiated cells can be trans-
formed by leukemia-associated oncogenes. Second, like
committed progenitors, transformation-susceptible cells retain
extensive, though limited, self-renewal potential. We hypothe-
sized that the ability of an oncogene to transform normal cells
may be largely determined by the transcriptome and epigenome
of the susceptible cell. By focusing on transformation-suscep-
tible cells, it may be possible to identify oncogene-independent
pathways that can be targeted in a wide range of leukemias,
largely independent of the transforming event.
TheMN1 gene was identified as a fusion partner of TEL, an ETS
transcription factor, in patients with AML or myelodysplastic
syndrome containing the translocation t(12;22)(p13;q11) (Buijs
et al., 1995). Gene expression analysis of MN1 in a large number
of human AML patients with normal cytogenetics showed that(I) Limiting-dilution transplantation analysis to determine the leukemia-initiating
(6 different cell doses [range 1–50,000 cells], 3–4 mice per cell dose).
(J) Cumulative CFC yield is shown for an initial plating of 1000 MN1-expressing
experiments).
(K) Immunophenotype of MN1 SP-HSC cells cultured in vitro. The GFP gate indic
and S2.high expression ofMN1 is an independent poor prognosticmarker
(Heuser et al., 2006; Langer et al., 2009). Functional studies have
demonstrated that overexpression of MN1 alone produces an
aggressive myeloid malignancy (Carella et al., 2007; Heuser
et al., 2007). MN1 has also been shown to induce resistance to
the differentiation-inducing agent ATRA both in vitro and in AML
patients (Heuser et al., 2007). The MN1 locus was identified as
a common insertion site in insertional mutagenesis screens, and
functional collaboration of MN1 and NUP98-HOXD13 (Slape
et al., 2007), AML1 (Watanabe-Okochi et al., 2008), CBFB/
MYH11 (Carella et al., 2007), CALM-AF10 (Caudell et al., 2010),
HOXA9 (Heuser et al., 2009a), and MLL-ENL (Liu et al., 2010) has
been proven or suggested. Functional studies of MN1 in human
cells also point to a critical role of MN1 in leukemogenesis, as
overexpression ofMN1 in human CD34+ cord blood cells dramat-
ically enhanced the proliferative potential of these cells (Kandilci
and Grosveld, 2009), and knockdown of MN1 in human leukemia
cell lines reduced their proliferation (Liu et al., 2010).
The molecular mechanisms by which MN1 exerts its effects
are largely unknown. Whether MN1 primarily transforms HSCs
or myeloid progenitor cells is not known. We chose the MN1
model of leukemia to characterize the variation in susceptibility
to transformation within normal hematopoietic cell populations
and to identify the genetic program(s) that determine suscepti-
bility to MN1-induced transformation.
RESULTS
CMPs but Not GMPs Are Susceptible to MN1-Induced
Transformation
To identify the cell of origin in murine MN1 leukemias, we em-
ployed retroviral transduction of single cell-sorted hematopoietic
progenitor cells (Figure S1A, available online). Single HSCs,
CMPs, GMPs, MEPs, or mature myeloid cells were fluores-
cence-activated cell sorted (FACS) according to previously
established immunophenotypes into wells of a 96-well plate
(Table S1), which had been coated by irradiated viral producer
cells producing MN1IRESeGFP virus. Sorting of progenitor pop-
ulations from 10- to 12-week old mice yielded cell purities
greater than 90% and demonstrated the expected enrichment
in colony-forming units and differentiation potential of CMPs,
GMPs, and MEPs into myeloid and erythroid, myeloid, or prefer-
entially erythroid lineages, respectively (Figures S1B–S1D).
Transplantation of 1.5–2.2 3 104 sorted CMPs, GMPs, or
MEPs into irradiated recipient mice (n = 3) resulted, as expected,
in only transient engraftment (data not shown). Of 768 single
sorted CMPs and GMPs, 11% and 1% of the clones, respec-
tively, proliferated over a period of 6 days to form a microscopi-
cally visible cell mass (Table S2). Only CMP clones, but not GMP
clones, were immortalized by MN1 in vitro and induced leuke-
mias in vivo (Figure 1). MN1-transduced CMP clones could be
serially replated in CFC assays up to and beyond the fifthcell frequency in MN1-CMP compared to bulk infected bone marrow cells
cells derived from a single cell sorted SP-HSC (mean ± SD of 3 independent
ates that all cells are transduced with MN1. See also Figure S1 and Tables S1
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(Figures 1A, 1B, and 1C). MN1-CMP leukemias showed a high
proportion of myeloid blasts in bone marrow (Figure 1D), infil-
trated spleen (Figures 1E and 1F), and liver (data not shown)
and had an immature immunophenotype (high c-kit expression)
with some expression of myeloid markers Gr-1 and CD11b,
similar to MN1 leukemias generated by transduction of 5-FU
treated bulk bone marrow cells (Figure 1G). In contrast to
MN1-bulk leukemias, expression of the B cell marker B220
was increased in MN1-CMP leukemias. Strikingly, the CMP
phenotype was highly preserved in MN1-CMP cells that were
cultured in vitro for 49 days (Figure S1E) and in leukemic bone
marrow cells from diseased mice (Figure 1H). Limiting-dilution
analysis using in vitro cultured MN1-CMP and MN1-bulk cells
showed that the LIC frequency was similar in both models
(MN1-CMP, 1 LIC in 1180 cells; MN1-bulk, 1 LIC in 5464 cells).
Thus, leukemias derived from bulk infections and from sorted
CMPs share most characteristics, suggesting that CMPs
constitute the main target population for MN1-induced
transformation.
To further investigate whether GMPs are susceptible to MN1-
induced transformation, GMPs were sorted and 150–4000 bulk
cells were transduced with MN1 (12 independent experiments).
Transduction efficiency ranged from 35%–48% (Figure S1F).
None of these cultures yielded colonies in CFC assays or en-
grafted lethally irradiated mice (Table S2 and Figure 1B). Single
cell sorting of MEPs and granulocytes and infection with MN1
did not induce significant proliferation of clones (Table S1).
Single cell sorting of 89 HSCs using two different sorting strate-
gies (see Table S1) yielded 32 highly proliferating clones. Sixteen
clones were positive for MN1, and transduction efficiency was
68%–98% at day 10 after transduction. These cells proliferated
as immortalized cell lines in vitro, as demonstrated by their
capacity to serially replate in CFC assays (Figure 1J). In suspen-
sion culture, most cells expressed high levels of c-kit and were
negative for the mast cell marker IgER (Figure 1K). Surprisingly,
transplantation of MN1-transduced side population (SP)
HSCs from 6 clones into 14 mice resulted in only transient
engraftment in peripheral blood (6% ± 2.6% at 7 weeks), and
no leukemias developed up to 26 weeks after transplantation.
In summary, we show at the single cell level that CMPs, but
not GMPs or HSCs, are susceptible to MN1-induced
transformation.
Normal CMPs and LeukemicMN1Cells Share aCommon
Gene Expression Signature
To identify differences between CMPs and GMPs that may
explain the different susceptibilities to transformation, we
compared gene expression profiles of CMPs and GMPs to
expression profiles of bone marrow cells from MN1 leukemic
mice (GFP+) and mature myeloid bone marrow cells (Gr1+/
CD11b+) from healthy mice. Two hundred and sixty-two probe
sets corresponding to 205 genes were significantly differentially
expressed both between CMPs versus GMPs and MN1 versus
Gr-1+/CD11b+ cells (Table S3). Seventy-five percent of differen-
tially regulated genes in CMPs compared to GMPs were regu-
lated in the same direction in MN1 cells compared to mature
myeloid cells (Figure 2A and Figures S2A and S2B). The 40
most highly expressed overlapping genes included Meis1, Flt3,42 Cancer Cell 20, 39–52, July 12, 2011 ª2011 Elsevier Inc.and Mef2c (Figure 2B). Gene expression profiles of MN1 and
mature myeloid cells also showed that two other genes that
are important for hematopoietic stem cell self-renewal, Hoxa9
andHoxa10, were upregulated in MN1 cells. This was confirmed
by quantitative RT-PCR comparing MN1 transformed with
freshly isolated total bone marrow cells (Figure S2C). Gene
expression ofMeis1, Flt3, HoxA9, and HoxA10 was significantly
downregulated in GMPs compared to CMPs or HSCs (stem and
progenitor cells defined by the LSK phenotype) as measured by
Affymetrix gene expression profiles (Figure 2C).
When we evaluated endogenous Mn1 gene expression in
murine hematopoietic stem/progenitor and mature cell popula-
tions by quantitative RT-PCR, we found that Mn1 expression
was elevated in HSCs (defined by the LSKFLT3-negative pheno-
type), lymphoid-primedmultipotent progenitors (LMPPs), CMPs,
and MEPs but was dramatically downregulated in GMPs and
mature cells of different hematopoietic lineages (Figure 2D).
Interestingly, this expression pattern was almost identical for
Meis1 (Figure 2D). Whereas expression of HoxA9 was similar in
HSCs, CMPs, and GMPs, HoxA10 expression was much lower
in CMPs, GMPs and more mature cells than in HSCs (Figure 2D).
Overexpression of MEIS1 Renders GMPs Susceptible
to MN1-Induced Transformation
Based on the above data, we hypothesized that the CMP-
specific gene expression signature determined susceptibility to
MN1-induced transformation and that reactivation of this signa-
ture in GMPsmay render GMPs susceptible toMN1. GMPswere
sorted and cotransduced with MN1 expressed from the SFFV
promoter and either a control vector or selected genes of the
CMP/MN1 signature (MEIS1, FLT3, HOXA9, HOXA10, RBPMS,
GATA2, PLEK, FYN, or NRIP1). Cells were subsequently plated
in CFC media and evaluated for serial replating capacity
in vitro and, in instances where colonies were formed, for
leukemia induction in vivo (Figure S3A). Transduction of GMPs
with MN1 and a control vector did not induce colony growth in
CFC assays (n = 12, Table S2, Figures 3A and 3B). Also, GMPs
transduced with MEIS1 and a control vector did not produce
colonies (n = 4, Figures 3A and 3B). Strikingly, however, cotrans-
duction of MN1 andMEIS1 in GMPs induced colony growth in 16
of 22 experiments (Table S2, Figure 3A). Double-transduced
cells could be replated up to and beyond the eighth replating
(Figure 3B). This result was also obtained when MN1 was ex-
pressed from the MSCV promoter. All cells from the first CFC
plating were positive for both MN1 and MEIS1, as demonstrated
by FACS analysis (Figure 3C). The cells grew as packed colonies;
65% of cells had macrophage morphology, while 28% of cells
had blast-like morphology (Figure 3D). The cells were negative
for the mast cell marker IgER and expressed markers typical of
MN1 cells (high proportion of c-kit and Flt3, low proportion of
CD11b and Gr-1 expressing cells; Figure 3E).
Cotransduction of MN1 and HOXA9 also immortalized GMPs
in 5 of 5 experiments (Figures 3A and 3F). However, HOXA9
with a control vector also immortalized GMPs, and thus
not all cells were double transduced with MN1 (Figure 3C).
MN1+HOXA9 and CTL+HOXA9 GMPs had a similar CFC output
during the first two replatings (Figure 3F). MN1+HOXA9 trans-
duced GMPs grew as packed colonies in which 50% of cells
had blast-like morphology (Figure 3D), whereas CTL+HOXA9
Figure 2. Normal CMPs and Leukemic MN1
Cells Share a Common Gene Expression
Signature
(A) Venn diagram of genes upregulated in CMPs
compared to GMPs and in leukemic MN1 bone
marrow cells compared to normal Gr1+/CD11b+
bone marrow cells.
(B) Heatmap of top 40 overexpressed genes in
CMPs compared to GMPs (n = 4, mean expres-
sion) that were also upregulated in MN1 leukemic
bone marrow cells when compared to normal
Gr1+/CD11b+ cells (n = 2, mean expression).
(C) Gene expression of Meis1, Flt3, HoxA9, and
HoxA10 measured on Affymetrix microarrays
and normalized to expression of Abl1 (n = 4,
mean ± SD).
(D) Gene expression of endogenous Mn1, Meis1,
HoxA9, and HoxA10 in hematopoietic progenitor
and mature cell populations relative to Abl1
expression measured by quantitative RT-PCR.
Data was normalized to the first measurement in
HSCs (n = 3, mean ± SD; n.e., not expressed). See
also Figure S2 and Table S3.
#Enriched for HSCs by sorting lin-/Sca-1+/c-Kit+
cells.
xEnriched for HSCs by sorting lin-/Sca-1+/c-Kit+/
Flt3- cells.
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MN1 and HOXA10 immortalized GMPs in 5 of 5 experiments
up to and beyond the fourth CFC replating, whereas HOXA10
with a control vector could not immortalize GMPs (Figures 3A
and 3G). All cells from the first CFC plating were positive for
HOXA10, demonstrating the requirement of HOXA10 for MN1-
induced transformation of GMPs (Figure 3C). Approximately
70% of these cells had a blast-like morphology (Figure 3D).
Cotransduction of GMPs with FLT3, RBPMS, GATA2, PLEK,
FYN, or NRIP1 (see Figure S3B for expression levels) with
a control vector or with MN1 did not induce any colony formation
in CFCs (Figure 3A).
We next evaluated whether GMPs immortalized by MN1 and
MEIS1 could induce leukemia in mice. MN1/MEIS1-GMPs from
six independent experiments harvested from the first or up to
the fifth CFC plating were intravenously injected into lethally
irradiatedmice at cell doses ranging from 53 104 to 23 106 cells
per mouse. None of 27 mice showed long-term engraftment or
developed leukemia (Figure 3H). Similarly, MN1/HOXA9-GMP
cells also failed to engraft mice when 5 3 104 to 2.6 3 105 cells
were transplanted (Figure 3H). MN1/HOXA10-GMP cells from
three independent experiments harvested after the first or
second CFC replating induced leukemia in two mice trans-Cancer Cell 20, 3planted with 7.6 3 105 cells after 65 and
69 days, whereas no engraftment was
found in mice transplanted with 1 3 105
cells (Figure 3H). MN1/HOXA10-GMP
leukemias were characterized by large
blast-like cells (Figure S3C), high c-Kit
expression, and lack of expression of
lineage markers (Figure S3D). The LIC
frequency in these cells was calculatedas 1 LIC in 6.14 3 105 cells. These results suggested that trans-
formation of GMPs by MN1 in combination with MEIS1 or
HOXA9/A10 was less efficient than transformation of CMPs by
MN1 alone. We evaluated whether defects in homing of MN1/
MEIS1-GMPs could explain the lack of engraftment by trans-
planting 0.5–1 3 106 cells intrafemorally into lethally irradiated
mice. However, no long-term engraftment was noted in these
mice (n = 4, data not shown).
We next evaluated whether MN1/MEIS1-GMP cells could be
complemented by other genes of the CMP signature. MN1/
MEIS1-GMP cells were transduced with a control vector or
with HOXA9, HOXA10, GATA2, RBPMS, PLEK, FYN, NRIP1,
VEGFC, or PROCR (also known as EPCR) and transplanted
into lethally irradiated mice. Only mice receiving transplants
with MN1/MEIS1-GMP cells transduced with HOXA9 or
HOXA10 showed engraftment in peripheral blood at 4 weeks,
whereas all other mice did not show engraftment after 4 and
8 weeks (Figure 4A). Mice receiving transplants of MN1/
MEIS1-GMP cells transduced with HOXA9 or HOXA10 rapidly
succumbed to leukemia with a similar disease latency docu-
mented for MN1-CMP leukemic mice (Figure 4B). Immunophe-
notyping of mice demonstrated a myeloid phenotype (CD11b+,
Gr-1+) with overexpression of c-kit in these leukemias9–52, July 12, 2011 ª2011 Elsevier Inc. 43
Figure 3. Overexpression of MEIS1 Renders GMPs Susceptible to MN1-Induced Transformation
(A) Effect of cotransduction of MN1 and a gene selected from the CMP signature on GMPs. The number of experiments and the frequency of transformation of
GMPs, i.e., in vitro proliferation, is given.
(B) Sorted GMPs (150–4000) were retrovirally transduced for 2 days, cultured in suspension for 3 days, and plated in CFC media. Cumulative CFC yield is shown
(n = 4–10 independent experiments, mean ± SD).
(C) Transduction efficiency of GMPs cotransduced with MN1 and MEIS1, MN1 and HOXA9, or MN1 and HOXA10, evaluated at the end of the first CFC plating.
(D) Morphology of CFCs and corresponding cells of GMPs cotransduced with MN1 and MEIS1, MN1 and HOXA9, or MN1 and HOXA10, evaluated at the end of
the first CFC plating. Scale bars represent 100 mm (upper row) and 10 mm (lower row).
(E) Immunophenotype of leukemic GMPs immortalized by MN1 and MEIS1 cotransduction. Cells were analyzed at the end of the first CFC plating (mean ± SD).
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Figure 4. Complementation of MN1/MEIS1-
GMPs and of MN1 SP-HSCs with an Addi-
tional Gene of the CMP Signature
(A) Effect of transduction of MN1/MEIS1-GMPs
with genes of the CMP signature on engraftment
levels in peripheral blood 4 weeks after trans-
plantation (mean ± SD).
(B) Survival analysis of mice receiving transplants
of MN1/MEIS1-GMPs transduced with a control
vector (n = 8), HOXA9 (n = 7), or HOXA10 (n = 3).
(C) Immunophenotype of a leukemic mouse at
death that received a transplant of MN1/MEIS1-
GMPs transduced with HOXA10. Numbers are
percent of MEIS1-YFP/HOXA10-GFP-positive
cells.
(D) Gene expression of hematopoietic transcrip-
tion factors in sorted ESLAM cells, MN1 SP-HSCs,
CMPs, and GMPs relative to Abl1. Expression in
ESLAM cells was used to calibrate the data in the
other cell types (mean ± SD).
(E) Survival analysis of mice receiving transplants
of MN1 SP-HSCs transduced with a control vector
(n = 7), MEIS1 (n = 7), or MEIS1+HOXA9 (n = 8).
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vector, MEIS1, and HOXA10. Whereas one mouse died from
leukemia after 52 days, the other mice remained healthy for at
least 70 days (Figure 4B).
To investigate whether MN1 SP-HSC cells retained a similar
gene expression profile compared to HSCs, we measured
expression levels of genes previously associated with self-
renewal and myeloid differentiation in HSCs, MN1 SP-HSCs,
LSK cells, CMPs, and GMPs. Meis1, Flt3, and Bmi1 were ex-
pressed at similar levels in MN1 SP-HSCs as in HSCs, whereas
HoxA9, HoxA10, and Gata2 were expressed at lower levels,(F) Cumulative CFC yield is shown for GMPs transduced with MN1 and HOXA9 or HOXA9 and a control vect
(G) Cumulative CFC yield is shown for GMPs transduced with MN1 and HOXA10 or HOXA10 and a control vec
(H) Survival analysis of mice receiving transplants of cells derived fromGMPs that were transduced withMN1 a
and HOXA10 (n = 8) and plated in CFCs. See also Figure S3.
Cancer Cell 20, 3possibly explaining the lack of engraft-
ment potential of MN1 SP-HSCs (Fig-
ure 4D). Therefore, we also performed
complementation experiments with
MEIS1 and HOXA9 in MN1 SP-HSCs.
Cotransduction of MEIS1 into these cells
did not enhance engraftment or develop-
ment of leukemia. However, cotransduc-
tion of MEIS1 and HOXA9 induced
leukemia in mice with a very short latency
(p < 0.001, Figure 4E). In summary, over-
expression of MEIS1 or HOXA10 in GMPs
can render GMPs susceptible to MN1-
induced in vitro immortalization, but not
in vivo transformation. HOXA9 overex-
pression in GMPs is sufficient for in vitro
immortalization, but even the combined
expression of HOXA9 and MN1 in GMPs
does not induce leukemias in vivo. Coex-
pression of MN1, MEIS1, and one of theAbdB-like HOX proteins HOXA9 or HOXA10 in GMPs readily
induces leukemia in mice. Finally, MN1 SP-HSCs have low
expression of HOXA9 and HOXA10 compared to HSCs, and up-
regulation of MEIS1 and HOXA9 restores leukemic activity of
these cells in vivo.
MN1 and MEIS1 Co-Occupy Select Promoter Regions of
Putative Direct Target Genes
It is well known that AbdB-like HOX proteins (HOXA9 to HOXA13)
directly interact with MEIS1 to enhance their DNA binding spec-
ificity (Shen et al., 1997). Based on our findings thatMN1 requiresor (n = 2–5 independent experiments, mean ± SD).
tor (n = 2–5 independent experiments, mean ± SD).
ndMEIS1 (n = 27), MN1 andHOXA9 (n = 4), or MN1
9–52, July 12, 2011 ª2011 Elsevier Inc. 45
Figure 5. MN1 and MEIS1 Co-Occupy Promoter Regions of Putative Direct Target Genes
Results of ChIP-Sequencing using an anti-HA antibody in MN1-HA leukemic cells or MEIS1-HA+ND13 leukemic cells and comparison with published data using
anti-MEIS1 and IgG control antibodies in HPC-7 cells.
(A) Total number of peaks for MN1 and MEIS1 libraries and distribution of peaks in promoter, intragenic, and intergenic regions.
(B) Proportion of chromatin peaks that are shared byMN1 andMEIS1 (at least 50%overlapping sequence). The expected overlap of chromatin peaks of a random
sample containing 37,682 peaks with MN1 peaks is shown for comparison.
(C) Histogram showing the distance between peak maxima of MN1 peaks to their closest MEIS1 peak, indicating that MN1 binding sites are highly enriched at
MEIS1 binding sites. The distance of random peaks to their closest MEIS1 peak shows no enrichment.
(D) The distance between peakmaxima ofMN1 peaks to their closestMEIS1, OCT4, SOX2, or NANOGpeak is plotted against the percentage of peaks having that
distance to their neighboring peaks.
(E) Algorithm to identify putatively direct target genes of MN1 and MEIS1. Differentially expressed genes in MN1 leukemia bone marrow compared to normal
Gr-1+/CD11b+ bone marrow cells or in MEIS1-HA+ND13 leukemic compared to CTL+ND13 nonleukemic cells were identified (R2-fold). Chromatin peaks of
MN1 or MEIS1 that fell within ± 5 kb of the genomic extents of differentially expressed genes were selected, and identical peaks and target genes of MN1 and
MEIS1 datasets were identified.
(F) Number and proportion of putatively direct target genes that are unique or shared between MN1 and MEIS1.
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Cell of Origin in MN1 LeukemiaMEIS1 and an AbdB-like HOX protein for full transformation of
GMPs, we hypothesized that MN1 may rely on interaction with
the MEIS1/HOX protein complex. To investigate whether MN1
and MEIS1 co-occupy similar target genes, we performed chro-
matin immunoprepitation (ChIP)-sequencing on MEIS1-
HA+ND13 and MN1-HA leukemic cells using an anti-HA anti-
body. These data were complemented by ChIP-sequencing
data using an anti-MEIS1 antibody and a control IgG antibody
in HPC-7 cells, published previously (Wilson et al., 2010).
Sequencing yielded more than 15 million mappable reads per
sample. Using a threshold of height 5 (MN1) or 6 (MEIS1), 73,756
and 37,682 enriched ChIP-seq regions (referred to as ‘‘peaks,’’
from genome browser visualizations) were identified for MN1
and MEIS1, respectively, of which most were located in inter-
genic regions (Figure 5A). Of all MN1 peaks, 31.1% had at least
50% sequence overlap with MEIS1 peaks, and 62.9% of MEIS1
peaks overlapped with MN1 peaks, whereas the expected over-
lap of a random sample is 1.6% (Figure 5B). Peaks shared by
MN1 and MEIS1 that were within regulatory regions of genes,
defined as 5 kb proximally or distally of the genomic location
of Refseq genes, were associated with 1975 targeted genes
(whereas ‘‘targeted gene’’ refers to a gene having an MN1 or
MEIS1 peak within its regulatory region). Plotting the distance
of the peak maxima of MN1 peaks to their closest MEIS1 peak
showed that a large number of MN1 peaks directly overlapped
MEIS1 peaks (Figure 5C). Seventy-five percent of MN1 peaks
were located within 1000 bp of the next MEIS1 peak, whereas
only 1%–2% of MN1 peaks were located within 1000 bp of the
next OCT4, SOX2, or NANOG peaks determined in a previous
study in mouse embryonic stem cells (Chen et al., 2008b)
(Figure 5D).
We next identified MN1-regulated genes (n = 3480) by
comparing gene expression profiles of bone marrow cells from
MN1 leukemic mice and mature myeloid bone marrow cells
(Gr1+/CD11b+) from healthy mice. Similarly, MEIS1-regulated
genes (n = 7252) were identified by comparing gene expression
profiles of MEIS1-HA+ND13 transduced leukemic cells with
CTL+ND13 transduced nonleukemic bone marrow cells (Argiro-
poulos et al., 2008). Eight hundred and fifty-eight genes were
regulated by MN1 and MEIS1. To identify directly targeted and
regulated genes of MN1 and MEIS1, peaks from ChIP-Seq
were intersected with regulatory regions of differentially
expressed genes (Figure 5E, Tables S4–S6). Compared to
Gr1+CD11b+ cells, approximately half of the MN1 targeted
and regulated genes were upregulated, while the other half
was downregulated. Approximately one-quarter of MEIS1 tar-
geted and regulated genes were upregulated, whereas the other
genes were downregulated. The majority of common MN1 and
MEIS1 target genes were regulated in the same direction
(82.5%, 72% down, 10.5% up); 18.6% and 17.1% of genes
targeted and regulated by MN1 or MEIS1, respectively, were
regulated and targeted by both MN1 and MEIS1 (n = 537 genes,(G) UCSC genome browser visualization of MN1, MEIS1, and control sequencing
from anti-HA antibody and from anti-MEIS1 antibody immunoprecipitations (Wilso
region (corresponding to FLT3-1 in Figure 5G).
(H) Validation of selected ChIP-Seq peaks shared byMN1 andMEIS1, targeted on
immunoprecipitates of MN1 or MEIS1 from MN1-HA or MEIS1-HA+ND13 leuke
(n = 3, mean ± SD). See also Tables S4, S5, S6, S7, S8 and S9.Figure 5F). The location of chromatin peaks of MN1, MEIS1, or
the peaks shared by MN1 and MEIS1 within regulated genes
are provided in Tables S7–S9.
Gene set enrichment analysis was performed with MN1
targeted and regulated genes or their overlap with MEIS1
targeted and regulated genes using the Gene Ontology (collec-
tion C5) and curated gene sets (collection C2, http://www.
broadinstitute.org/gsea/msigdb/index.jsp). The most highly en-
riched gene sets were ‘‘hematopoiesis related transcription
factors’’ and several AML and HOXA-related gene sets. We
found fewer significantly depleted gene sets, and they had lower
normalized enrichment scores than enriched gene sets. Several
depleted gene sets were related to apoptosis.
To validate the ChIP-Seq results, we compared our MEIS1
library with published ChIP-Seq data in which an anti-MEIS1
antibody was used (Wilson et al., 2010). Comparison of the two
datasets showed a very high degree of overlap (56.4% of the
peaks identified by Wilson et al. were also found in our dataset).
As shown for the FLT3 gene, the peaks directly matched each
other (Figure 5G). An IgG control ChIP-Seq data set published
by Wilson et al. (2010) confirmed the specificity of MN1 and
MEIS1 peaks (Figure 5G). Representative chromatin peaks
were also validated by qPCR looking at target regions of both
MN1 and MEIS1 or MN1 alone (Cdh3 is only targeted by MN1)
and control regions not targeted by the two proteins. Whereas
all randomly selected chromatin regions showed significant
enrichment for both MN1 and MEIS1 (except the Cdh3 gene
for MEIS1), no enrichment was found in the control regions (Fig-
ure 5H). In summary, these data identify putative direct target
genes of MN1 and MEIS1, and show co-occupancy of MN1
andMEIS1 at 18.6% and 17.1% of their respective target genes.
A Dominant-Negative Form of MEIS1 Demonstrates
Antileukemic Activity in Established MN1 Leukemias
Next, we evaluated the role of Meis1 for maintenance of estab-
lished MN1 leukemias. Recently, we demonstrated that an engi-
neered fusion protein of the repressive domain of M33 to MEIS1
(M33MEIS1) confers transcriptional repression to MEIS1 target
genes that are otherwise upregulated in normal and malignant
hematopoiesis (Argiropoulos et al., 2010). Transduction of
M33MEIS1 or a control vector in MN1 leukemic cells resulted
in a reduction of CFCs at the end of the first plating (Figure 6A).
Whereas CTL-transduced MN1 cells retained the CTL vector
during CFC culture, the majority of M33MEIS1 transduced cells
were lost during CFC culture (Figure 6B). Double-transduced
MN1+CTL or MN1+M33MEIS1 expressing cells, which had
a double transduction rate of 55%–95%, with or without sorting,
were injected into lethally irradiated recipient mice (5 3 104 to
7.5 3 105 cells per mouse). Six weeks after transplantation,
approximately 70% of peripheral blood cells frommice receiving
MN1+CTL transduced cells were positive for MN1 and the CTL
vector, whereas 18% were positive for MN1 only. Strikingly,tracks at the FLT3 locus showing exactly matching peaks for MN1 and MEIS1
n et al., 2010). The insert shows an enlarged view of the main peak in the FLT3
ly by MN1 (CDH3), and not targeted by either MN1 or MEIS1 (CTL). Chromatin-
mic cells, respectively, were quantified by qPCR and compared to input DNA
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Figure 6. A Dominant-Negative Form of MEIS1 Demonstrates Antileukemic Activity in Established MN1 Leukemias
(A) Number of colonies from first plating of MN1 cells transduced with a control vector or M33MEIS1 (n = 3, mean ± SD).
(B) Proportion of double-transduced cells before and after the first CFCplating. MN1+CTL transduced cells retained expression of the control vector, whereas the
proportion of cells expressing M33MEIS1 greatly decreased during CFC culture.
(C) Engraftment of MN1 cells transduced with CTL (n = 5) or M33MEIS1 (n = 4) in recipient mice 6 weeks after transplantation. The proportion of double- or single-
transduced donor-derived cells in peripheral blood is shown (mean ± SD).
(D) Representative FACS blots from peripheral blood of mice receiving transplants of MN1 cells transduced with CTL or M33MEIS1 are shown.
(E) Gene expression of target genes of MN1 and MEIS1 (Cdh3 is only targeted by MN1) in MN1 and MN1+M33MEIS1 cells relative to Abl1 (log2). MN1 cells were
used to calibrate the data in the other cell type (mean ± SD, n = 3).
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MN1+M33MEIS1-transduced cells expressed MN1 and
M33MEIS1, whereas 95% of cells only expressed MN1 (p <
0.001, Figure 6C). Representative FACS blots from two mice
per group are shown in Figure 6D. Gene expression analysis
of validated targets of MN1 and/or MEIS1 in MN1 or
MN1+M33MEIS1 cells confirmed the repressive effect of
M33MEIS1 on several of its target genes. Of note, Cdh3, which
is not targeted by MEIS1, was not repressed by M33MEIS1.48 Cancer Cell 20, 39–52, July 12, 2011 ª2011 Elsevier Inc.These data suggest that M33-MEIS1 inhibits proliferation by
interfering with MEIS1 transcriptional activity and, so, prevents
engraftment of MN1 leukemias in mice.
DISCUSSION
Oncogenic transformation is generally regarded as a multistep
process and it has been difficult to recapitulate this process in
a step-wise order. A critical question is whether leukemias arise
Cancer Cell
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but maintain their self-renewal potential or whether self-renewal
is reactivated in more differentiated cells, thus giving rise to
leukemia stem cells. We used the MN1 model of leukemia to
address this question, as constitutive activation of a single
gene, MN1, induces AML by enhancing self-renewal and by
blocking differentiation through distinct functions of the gene
(Heuser et al., 2007). We identified CMPs, but not GMPs, as
the cells of origin in MN1 leukemias. Susceptibility to MN1 was
determined by the activity of MEIS1 and AbdB-like HOX protein
complexes. We show that MN1 and MEIS1 colocalize at the
chromatin level and that expression of a dominant-negative
form of MEIS1 abolishes leukemogenicity of established MN1
leukemias.
Prospective isolation and transduction of single cells demon-
strated susceptibility of CMPs (but not GMPs, MEPs, or more
differentiated myeloid cells) to MN1-induced transformation.
Our approach of directly infecting single cell-sorted hematopoi-
etic progenitor cells, thus preventing interaction of hematopoi-
etic cells by cell-cell contact, has not been reported previously.
Wang et al. used a similar approach, where a bulk of sorted
progenitor cells was infected and transduced cells were subse-
quently single cell sorted into wells of a 96-well plate (Wang et al.,
2010). We investigated whether earlier stages of the hematopoi-
etic hierarchy could also be transformed by MN1. Although
HSCs were sorted to a high purity and showed a striking prolifer-
ative potential in suspension culture, MN1-transduced HSCs did
not induce leukemia in mice. Only contransduction of MEIS1 and
HOXA9 restored the leukemic potential in vivo. Expression anal-
ysis suggested thatMeis1 expression levels were similar in MN1
SP-HSCs and sorted HSCs, but HoxA9 and HoxA10 levels were
reduced. It remains unclear why expression of MN in SP-HSCs
cannot sustain expression of HOXA genes, but additional factors
that are differentially expressed between HSCs and CMPs likely
play a role. Our retroviral approach may have been insufficient to
target the HSC at its earliest stage. Interestingly, transduction of
sorted LMPPs with MN1 rapidly induced leukemias in mice (data
not shown). Thus, the spectrum of susceptible cells to MN1-
induced transformation is the CMP and multipotent progenitor
cell stage, but it may not extend to themost primitive HSC stage.
We determined the LIC frequency of MN1 leukemias derived
from bulk infected bone marrow cells and from single cell sorted
CMPs transduced with MN1. In both cases, transduced cells
were cultured for 3weeks and the LIC frequencywas determined
from these cultured cells. The LIC frequency in MN1-bulk cells
was very similar to that in MN1-CMPs. It is thus interesting that
MN1 leukemias have a fairly constant LIC frequency under in vitro
culture conditions, apparently independent of the cell of origin.
A recent study characterized the phenotype of LICs in human
AML and found LICs in both LMPP-like and GMP-like popula-
tions. However, whether these populations were also cells of
origin in these patients can not be addressed in primary disease
(Goardon et al., 2011).
Prospective isolation and transduction of single sorted GMPs
with MN1 did not immortalize cells in vitro. Because technical
issues cannot be excluded in single cell sorting and infection,
we sorted GMPs and infected up to 4000 GMPs in bulk cell
culture. Again, no immortalized cell line could be derived.
Cotransduction of MN1 with MEIS1, HOXA9, or HOXA10, butwith none of the other genes tested, resulted in immortalized
cell lines in vitro. Interestingly, MN1/MEIS1 cotransduced
GMPs did not engraft mice. Similar findings were recently re-
ported for HOXA9/MEIS1 cotransduced GMPs that were immor-
talized in vitro but could not engraft mice (Wang et al., 2010). In
contrast, the fusion oncogenes MLL-ENL (Cozzio et al., 2003),
MLL-AF9 (Krivtsov et al., 2006), and MOZ-TIF2 (Huntly et al.,
2004) have been shown to fully transform GMPs, giving rise to
leukemias in vivo. Our results indicate that HOXA9 is the only
natural gene reported thus far that can immortalize GMPs
in vitro. Full transformation of GMPs to leukemia by MN1
required an AbdB-like HOX gene in addition to MEIS1. In
summary, we generated a model in which we could track the
requirement of several genes and pathways that determine
transformation susceptibility in hematopoietic progenitor cells.
MEIS1 is a cofactor of AbdB-like HOX proteins and directly
interacts with HOXA9, HOXA10, and other AbdB-like HOX
proteins (Shen et al., 1999). It is well established that AbdB-like
HOX proteins stabilize DNA binding of MEIS1 and enhance tran-
scriptional activation of its target genes (Shen et al., 1997). Our
results demonstrate that MN1 requires active MEIS1 and
AbdB-like HOX gene expression for transformation. Activation
of only one factor of this complex in GMPs is sufficient for
in vitro immortalization, but not for in vivo transformation. Impor-
tantly, our data suggest that MN1 can only maintain MEIS1 or an
AbdB-like HOX gene signature in CMPs, not induce expression
of MEIS1 or AbdB-like HOX genes in GMPs. We have previously
shown that constitutive activation of HOXA9 to MN1-trans-
formed cells dramatically enhanced the frequency and self-
renewal of leukemia stem cells (Heuser et al., 2009a), supporting
the role of AbdB-like HOX proteins as cooperating transcription
factors for MN1. The MLL fusion proteins MLL-ENL and MLL-
AF9 can fully transform GMPs when retrovirally expressed at
high levels (Chen et al., 2008a; Cozzio et al., 2003; Krivtsov
et al., 2006), in part by activating MEIS1 and HOXA9 expression
(Zeisig et al., 2004). However, Wang et al. (2010) recently
described that constitutive expression of MEIS1 and HOXA9 in
GMPs cannot fully transform GMPs. They found that b-catenin
expression, an activator of the WNT pathway and a target
gene of MLL-AF9, in HOXA9/MEIS1-transduced GMPs readily
transforms these cells in vivo (Wang et al., 2010). It can be spec-
ulated that MN1 might be an activator of the WNT pathway
collaborating with HOXA9/MEIS1 in GMP transformation. How-
ever, previous data on the downstream targets of MN1 did not
establish a link between MN1 and the WNT pathway. Besides,
gene expression profiling studies of murine leukemias have not
revealed MN1 as a target gene of MLL fusions (Chen et al.,
2008a; Somervaille et al., 2009). Thus, it is possible that MN1
complements HOXA9/MEIS1 transformation of GMPs indepen-
dently of the WNT pathway, representing an additional pathway
collaborating with HOXA9/MEIS1 in GMPs.
In our study, MN1 was expressed at high levels in CMPs but
downregulated in GMPs, and single cell infection of CMPs by
MN1 arrested the cells phenotypically at the CMP stage. In
contrast to a previous report that found the highest MN1 expres-
sion levels in GMPs (Carella et al., 2007), these data suggest that
MN1 negatively regulates the transition from CMPs to GMPs in
normal hematopoiesis. ChIP-sequencing analysis showed that
MN1 and MEIS1 strikingly co-occupy regulatory regions of theirCancer Cell 20, 39–52, July 12, 2011 ª2011 Elsevier Inc. 49
Figure 7. Schematic Highlighting the Interplay of a Constitutively
Active Oncogenic Pathway and Variable Stages of Cellular Suscep-
tibility to Transformation
The ‘‘susceptibility pathway’’ may represent a therapeutic target in multiple
leukemic entities, whereas the oncogenic pathway represents a therapeutic
target specific for the dysregulated pathway.
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an active chromatin state of MEIS1 loci was critical for self-
renewal of normal and leukemia stem cells (Wong et al., 2007);
thus, we tested whether transcriptional repression of MEIS1
loci may reduce leukemogenicity of established MN1 leukemias.
We fused the repressive domain of M33, a member of the Poly-
comb group, to MEIS1. This fusion has been shown to facilitate
Polycomb group complex formation at direct MEIS1 target
genes and to result in transcriptional repression of these genes
(Argiropoulos et al., 2010). Interestingly, leukemogenic activity
of MN1 was abolished by the M33MEIS1-fusion protein, con-
firming that a functional MEIS1 is critical for MN1 function.
MEIS1, HOXA9, and HOXA10 have been extensively charac-
terized as genes of the self-renewal signature in normal and
malignant hematopoiesis (Krivtsov and Armstrong, 2007). The
aim of the present study was to identify pathways that determine
transformation susceptibility to MN1. Our results highlight the
critical role of the normal cell in oncogenic transformation. In
our model, the oncogene has a constant level of activity, while
the activity of the susceptibility-regulating pathway declines
with differentiation of the target cell (Figure 7). Susceptibility to
the oncogene in our study was determined by the well-charac-
terized self-renewal genes MEIS1, HOXA9, and HOXA10. We
suggest that the susceptibility pathway represents an indepen-
dent therapeutic target besides the transforming event that
induces the malignancy. Inhibition of this pathway, e.g., by tran-
scriptional repression of target loci, as exemplified by M33-
MEIS1, appears to be a promising strategy for the treatment of
AML, and targeting this self-renewal pathway may be effective
in a wide range of leukemias.
EXPERIMENTAL PROCEDURES
A detailed description of experimental procedures can be found in the
Supplemental Information.
Retroviral Vectors and Vector Production
Retroviral vectors for expression of MN1 (Heuser et al., 2007), MEIS1 (Pineault
et al., 2003), M33MEIS1 (Argiropoulos et al., 2010), FLT3(Palmqvist et al.,
2006), HOXA9 (Kroon et al., 1998), HOXA10 (Buske et al., 2001), and ND1350 Cancer Cell 20, 39–52, July 12, 2011 ª2011 Elsevier Inc.(Pineault et al., 2003) have been described previously. MN1 was subcloned
in the MSCVPGKneo vector, and an HA-tag was cloned to the C terminus of
MN1 in the pSF91-MN1-IRESeGFP vector. Gateway cloning was used to
clone human cDNAs of RBPMS, GATA2, PLEK, FYN, NRIP1, VEGFC, and
PROCR upstream of IRESeGFP in expression vector pSF91IRESeGFP-
RfA-EXPR.
FACS Sorting of Hematopoietic Progenitor Cells
Freshly isolated cells from murine bone marrow were used for fluorescence
activated cell sorting (FACS) of hematopoietic progenitor or differentiated
cell populations. For sorting of single progenitor cells, we first enriched the
cells by sorting c-kit expressing cells. Cells were then stained as detailed in
Table S1 and as described before (Akashi et al., 2000; Heuser et al., 2007),
and single cells were deposited into wells of a round-bottom 96-well plate.
Sorting of other populations was performed as detailed in the Supplemental
Information.
Transduction and Culture Conditions of Single Cell Sorted
Hematopoietic Progenitor Cells
One day before transduction was initiated, GP+E86 viral producer cells were
irradiated with 4000 cGy, and plated in wells of a round-bottom 96-well plate
containing 100 ml medium at a density of 3.3 3 104 cells per well. Single cell
deposition into wells of a test plate was visually confirmed before single
progenitor cells were directly sorted into wells of a 96-well plate. Cells were
cocultured for 48 hr in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 15% fetal bovine serum (FBS), 10 ng/mL human interleukin-6
(hIL-6), 6 ng/mL murine interleukin-3 (mIL-3), and 20 ng/mL murine stem cell
factor (mSCF; all from StemCell Technologies, Inc., Vancouver, Canada). After
48 hr, cells were replated in an empty 96-well plate and 100 ml fresh medium
were added. When cells proliferated to a microscopically visible cell mass,
they were replated and used in CFC assays or mouse transplantation.
Mice and Retroviral Infection of Primary Bone Marrow Cells
and Bone Marrow Transplantation
C57BL/6J mice were bred and maintained in the animal research center of the
British Columbia Cancer Agency as approved by the University of British
Columbia Animal Care Committee. Primary mouse bone marrow cells were
transduced after prestimulation for 48 hr, as previously described (Heuser
et al., 2009b). Briefly, cells were cocultured with irradiated viral producer cells
for 48 hr in the presence of 5 mg/mL protamine sulfate (Sigma-Aldrich) and then
plated in CFC media or directly transplanted into lethally irradiated syngeneic
recipient mice that were exposed to a single dose of 750 cGy total-body irra-
diation accompanied by a life-sparing dose of 1 3 105 freshly isolated bone
marrow cells from syngeneic mice.
Gene Expression Profiling and Gene Set Enrichment Analysis
MN1 leukemia cells and Gr-1+/CD11b+ bone marrow cells were hybridized to
the Affymetrix GeneChip Mouse430 2.0 (43.000 probes) microarray (n = 2)
according to the manufacturer’s instructions. Experiments were performed
at British Columbia Genome Sciences Centre, Vancouver, Canada. Gene
expression data can be found at the Gene Expression Omnibus database
(GEO accession number GSE22923). Gene expression profiling of CMPs
and GMPs using Affymetrix GeneChip Mouse430A array (22,690 probes)
has been described elsewhere (Krivtsov et al., 2006). Gene expression
profiling of MEIS1+ND13 and CTL+ND13 cells using Affymetrix GeneChip
Mouse430 array (43.000 probes) has been described previously (Argiropoulos
et al., 2008).
The gene set enrichment analysis software (Subramanian et al., 2005)
(http://www.broad.mit.edu/gsea/index.jsp) was used to compare enrichment
of curated gene sets (dataset C2) and Gene Ontology gene sets (dataset C5,
available from the Molecular Signature database v2.5 [Subramanian et al.,
2005]).
ChIP Assay and ChIP-Sequencing
Chromatin immunoprecipitation (ChIP) assays were performed using sequen-
tial cross-linking with disuccinimidyl glutarate (Sigma) and formaldehyde fol-
lowed by immunoprecipitation (see Supplemental Experimental Procedures)
using an anti-HA antibody (Abcam ab9110). qPCR was performed to verify
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sequencing was performed as described previously (Robertson et al., 2007).
Cluster generation and 50 bp sequencing on the Illumina Genome Analyzer
IIx (Illumina, San Diego, CA) was performed following the manufacturer’s
instructions. Details about library construction, processing of ChIP-Seq
data, and validation by ChIP-qPCR can be found in the Supplemental
Information.
Statistical Analysis
Pairwise comparisons were performed by Student’s t test for continuous
variables and by chi-square test for categorical variables. The two-sided level
of significance was set at p values less than 0.05. Comparison of survival
curves were performed using the log-rank test.
ACCESSION NUMBER
MN1-gene expression data can be found at the Gene Expression Omnibus
database (GEO accession number GSE22923).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, three figures, and nine tables and can be found
with this article online at doi:10.1016/j.ccr.2011.06.020.
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